Background: The prognostic significance of extramedullary leukemia (EML) in childhood acute myeloid leukemia is not clarified.
INTRODUCTION
Acute myeloid leukemia (AML) is a heterogeneous disease that accounts for about 20% of all leukemias in children. [1] [2] [3] Compared with acute lymphoblastic leukemia, children with AML have an inferior outcome with a 5-year estimated event-free survival (EFS) of approximately 50% and a 5-year estimated overall survival (OS) up to 70%. [4] [5] [6] [7] Extramedullary leukemia (EML), presenting as leukemic blast cells in the cerebrospinal fluid (CSF) or as a myeloid sarcoma frequently located to the skin, orbita, and gingiva, is a common finding in pediatric AML with reported frequencies varying from 18 to 25%. [8] [9] [10] The prognostic importance of central nervous system (CNS) disease as well as myeloid sarcoma is controversial, and the optimal treatment strategy for children presenting with extramedullary manifestations is not clear. Some studies have shown that CNS disease does not adversely affect survival. 8, 11 However, other study groups have found CNS disease to be a risk factor for isolated CNS relapse. 9, 12, 13 Only a few groups have examined the effect of myeloid sarcoma on survival, [8] [9] [10] 14 suggesting a poorer outcome for EML involving the skin. 14 The aim of this study was to characterize the clinical and prognostic 
PATIENTS AND METHODS

Patients
The study included children from 0 to 17 years of age diagnosed with Patients with Down syndrome, myelodysplastic syndrome, or acute promyelocytic leukemia were excluded.
The diagnosis of AML was established using standard techniques, and patients were classified morphologically according to the French-American-British (FAB) criteria. 15 Karyotypes were centrally reviewed annually by the NOPHO Cytogenetics Group. The karyotypes were described according to the International System for Human Cytogenetic Nomenclature (ISCN) 2009. 16 All patients had evaluable cytogenetic examinations.
We compared characteristics and outcomes of EML patients to those of non-EML patients. In addition, the EML group was subdivided into three subgroups: myeloid sarcoma, CNS disease, or myeloid sarcoma and CNS disease combined.
CNS disease was defined as ≥5 leukocytes per microliter of CSF and the presence of leukemic blast cells in the cytospin, and/or new neurologic symptoms (e.g., seizures, cranial nerve palsy, and signs of increased intracranial pressure). The presence of blasts and ≥5 leukocytes per microliter and/or the presence of new neurologic symptoms in a traumatic spinal tap were also considered as CNS disease. Myeloid sarcoma was defined as a tumor mass of myeloblasts or immature myeloid cells occurring in an extramedullary site. 17 The diagnosis was based upon biopsy studied by morphology and immunohistochemistry.
This study was based on data prospectively collected and registered in the NOPHO-AML 2004 protocol approved by the national ethics boards. Written informed consent was obtained from the parents or the legal guardians of the patients, and the study was conducted according to the Declaration of Helsinki.
Data collection
Since 1984, NOPHO has prospectively collected and registered data of all children diagnosed with AML and treated according to the NOPHO-AML protocols in the five Nordic countries. 18, 19 From November 2007, Hong Kong also joined the NOPHO-AML 2004 protocol and contributed to the data collection. The NOPHO-AML register is population based for children below 15 years of age.
Data on patient characteristics, treatment, follow-up, and outcomes were extracted from the NOPHO-AML database. A questionnaire regarding any use of radiation therapy in EML patients was sent to the treating physicians with a response rate of 100%.
Treatment
The NOPHO-AML 2004 protocol included two induction courses with AIET (cytarabine, idarubicin, etoposide, and 6-thioguanine) and AM (cytarabine and mitoxantrone), respectively, followed by four consolidation courses based on high-dose cytarabine. Additionally, patients were randomized to postconsolidation treatment with gemtuzumab ozogamicin. 19 Patients without CNS disease received one prophylactic, age- 
Statistical methods
The significance of observed differences in proportions between groups was tested using the 2 test and Fisher's exact test. For continuous variables, the Mann-Whitney U test was applied. The KaplanMeier method was used to calculate estimates of survival, and comparisons between survival distributions were made using the log rank test.
We calculated the cumulative incidence of relapse based on primary event data, treating death as a competing risk. We estimated risk differences (RDs, i.e., the absolute difference in 5-year cumulative risk) and risk ratios in EFS, OS, and relapse risk at 5 years after diagnosis using generalized linear modeling of the pseudo-observations. 20 The prognostic factors were examined in a multivariate analysis, including sex, age at diagnosis, initial white blood cell (WBC) count, FAB group, and 11q23 aberrations. The software applications SPSS Statistics Version 21 (SPSS Science, Chicago, IL) and Stata/IC Version 13.1 were used to perform the statistical analyses. P-values were two-sided, and values less than 0.05 were considered statistically significant. EFS was defined as the time from diagnosis to first event defined as resistant disease (event day 0), death during induction, or in remission from any cause, relapse, second malignancy, or last follow-up, whichever occurred first. OS was defined as the time from diagnosis to death from any cause or last follow-up. were excluded from the analysis due to missing data on the presence of EML, and a total of 315 patients were included. At diagnosis, 73 (23%) patients were reported to have EML. Of these, 39 (12%) had myeloid sarcoma, 22 (7%) had CNS disease, and 12 (4%) were diagnosed with both myeloid sarcoma and CNS disease. One patient with myeloid sarcoma was excluded from the subgroup analysis due to unknown CNS disease status.
RESULTS
By
Myeloid sarcoma was most frequently localized to the skin (n = 16) or the orbita (n = 11). Furthermore, myeloid sarcoma was detected in the following sites: lymph nodes (n = 5), gingiva/mouth (n = 3), abdomen (n = 2), infiltration of dura/epidural space (n = 2), and one each with involvement of sinus, mandible, maxilla, the mastoid process, neck, humerus, mediastinum, lung, pericardium, pancreas, appendix, retroperitoneum, kidney, adrenal glands (bilateral), labia majora, testes (bilateral), gluteal region, and thigh.
Of the 51 patients diagnosed with myeloid sarcoma, 39 had one involved site, eight had two involved sites, and three had three involved sites. One patient had missing information on the number of involved sites. Bilateral involvement of paired organs (e.g., orbita, testis, adrenal gland) was counted as one site only.
Patient characteristics
The characteristics of patients with non-EML, EML, myeloid sarcoma, and CNS disease are summarized in Table 1 . EML patients were younger than non-EML patients (median: 2.6 vs. 7.5 years; P < 0.001). Both hepatomegaly (47% vs. 34%; P = 0.046) and splenomegaly (33% vs. 21%; P = 0.03) were more frequent in EML patients compared to non-EML patients. A higher median WBC (40 vs. 20 × 10 9 /l; P = 0.047) was observed in patients with EML. A higher proportion of EML patients had M5 morphology (40% vs. 19%; P < 0.001) and 11q23 abnormalities, other than t(9;11), in comparison with non-EML patients (19% vs. 9%; P = 0.02).
Patients with myeloid sarcoma were younger at diagnosis than patients with CNS disease (median: 1.6 vs. 6.0 years; P = 0.07). A higher WBC was found in patients with CNS disease compared to patients with myeloid sarcoma (76 vs. 12 × 10 9 /l; P = 0.01). Significantly more patients with myeloid sarcoma had M5 AML (51% vs. 18%; P = 0.01), whereas significantly more patients with CNS disease had M4 AML (41% vs. 5%; P = 0.001). Finally, a higher proportion of patients with myeloid sarcoma had t(9;11) compared to those with CNS disease (24% vs. 0%; P = 0.02).
Comparing patients with skin myeloid sarcoma to patients with other types of myeloid sarcoma, we found skin myeloid sarcoma to be associated with 11q23, other than t(9;11), (31% vs. 9%; P = 0.09) as well as young age (median: 0.6 years vs. 3.9 years; P < 0.001). More patients with orbital myeloid sarcoma had t(8;21)(q22;q22) (36% vs. 10%; P = 0.06).
MLL rearrangements
We found MLL rearrangements in 25 (34%) EML patients, of whom 11 had t(9;11)(p21;q23) and 14 had other 11q23 aberrations (Table 1) . Although this was a very heterogeneous group, it was noteworthy that 50% of the patients with 11q23, other than t(9;11), had rearrangements involving chromosome 10. The t(10;11)(p12;q23) and ins(10;11)(p12;q23q13), which produce the MLL-AF10 fusion, were found in four patients, t(10;11)(p11.2;q23) was found in one patient, and two patients had MLL with 10p13 as rearrangement partner.
Radiation therapy
None of the patients, including the 73 with EML, received radiation therapy as part of their primary treatment. However, two EML patients received total body irradiation as part of the conditioning regimen for HSCT. The remaining seven EML patients who received HSCT in CR1 had busulfan-or clofarabine-based conditioning regimens.
Patient outcomes
The outcomes of patients with non-EML, EML, myeloid sarcoma, and CNS disease are listed in Table 1 and illustrated in Fig. 1 . No significant difference in remission rates was noted. The 5-year estimated EFS for EML and non-EML patients was 54% (95% confidence interval [CI] 42-65%) and 45% (95% CI 37-51%), respectively (P log rank = 0.57) (Fig. 1A) .
EML patients had a significantly lower 5-year OS of 64% (95% CI 51-74%) versus 73% (95% CI 66-78%) in the non-EML patients (P log rank = 0.04) (Fig. 1B) . The probability of survival was comparable for all three EML subgroups.
The cumulative incidence of relapse at 5 years was 33% (95% CI 23-47%) for EML patients and 49% (95% CI 41-56%) for non-EML patients (P log rank = 0.16) (Fig. 1C) . Fourteen EML patients experienced an isolated BM relapse, two patients had isolated CNS relapse, two patients had concurrent BM and CNS relapse, one patient had concurrent BM and testis relapse, and one had concurrent BM and other location relapse (see Table 1 ). Of the four patients with CNS relapse, three had CNS involvement at diagnosis. No patients relapsed at the primary site of the myeloid sarcoma.
Significantly more EML patients died during the induction therapy than non-EML patients (8% vs. 1%; P = 0.002). All six EML patients who died were females and had M5 morphology and of these, four patients (including two patients with CNS involvement at diagnosis) died as a result of cerebral bleeding or infarction. No significant differences in (27) 11 (29) 6 (27) Death in CR1 4 (2) 3 (4) 2 (5) 
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Relapse type, n (%) BM 87 (36)** 14 (19)** 9 (24) 3 (14) CNS 0 (0) 2 (3) 1 (3) 1 (5) BM + CNS 2 (1) 2 (3) 0 (0) 1 (5) BM + testis 0 (0) 1 (1) 0 (0) 1 (5) BM + other location 5 (2) 1 (1) 1 (3) 0 (0) Outcome, % The myeloid sarcoma and CNS disease groups are subgroups of the EML group. The number of patients with EML combined is not equal to the number of patients with myeloid sarcoma plus CNS disease, as 12 patients diagnosed with both myeloid sarcoma and CNS disease are not included in this table. CNS disease status was unknown for one patient diagnosed with myeloid sarcoma. This patient was not included in the subgroup analysis. Significance level: * P < 0.05; ** P < 0.01. EML, extramedullary leukemia; CNS, central nervous system; WBC, white blood cell; Hb, hemoglobin; BM, bone marrow; PB, peripheral blood; FAB, FrenchAmerican-British; FLT3, FMS-like tyrosine kinase-3; ITD, internal tandem duplications; ALM, activation loop mutation; NPM1, nucleophosmin; CR1, first complete remission; HSCT, hematopoietic stem cell transplantation; SMN, secondary malignant neoplasm; EFS, event-free survival; OS, overall survival. resistant disease or death in complete remission were found between the two EML groups.
Blood contamination of the spinal fluid (traumatic lumbar puncture defined as more than 10 erythrocytes × 10 6 /l) without detectable blasts was found in 47 patients (15%). These patients had a median age of 7.0 years, median WBC of 18 × 10 9 /l, and median peripheral blood blast percentage of 27. The 5-year EFS was 58% (P log rank = 0.13) and the 5-year OS was 82% (P log rank = 0.12). Fourteen (30%) of these patients experienced an isolated BM relapse and none had CNS relapse.
Prognostic factor analysis
Results of the multivariate analysis are shown in Table 2 . After adjusting for sex, age at diagnosis, initial WBC, FAB type, and 11q23 aberrations, the difference in 5-year relapse risk between EML and non-EML patients did not remain statistically significant (RD crude: -19%, 95% CI -32 to -5%; RD adjusted: -10%, 95% CI -24 to 4%). A similar pattern was found in the crude and adjusted risk estimates of 5-year EFS between the two groups (RD crude: 10%, 95% CI -4% to 25%; RD adjusted: 0.7%, 95% CI -14% to 15%). Adjustment for the above factors did not alter the risk estimates of 5-year OS between the two patient groups. Figure 2 illustrates the RD in 5-year OS between EML and non-EML patients in a number of subgroups. EML patients had a 9% nonsignificantly higher risk of dying at 5 years from diagnosis than non-EML patients. EML had no impact on survival for patients aged 0-1 year. A RD of -16% and -19% was noted for patients aged 2-9 years and 10+ years, respectively.
DISCUSSION
We found more cases of induction death among patients with EML compared to patients without EML. Conversely, there was a trend toward a lower risk of relapse for EML patients.
We found that significantly more patients affected with EML died during the induction phase of treatment, mainly as a result of cerebral bleeding or infarction, implying an inferior OS of the EML group. In a study from the Berlin-Frankfurt-Münster group, including 901 children, the main risk factors for death before day 15 were hyperleukocytosis and M5 morphology. 21 These results were in line with those F I G U R E 1 (A) Probability of event-free survival for EML patients and non-EML patients. EML 5-year estimated event-free survival 54% and non-EML 5-year estimated event-free survival 45% (P log rank = 0.57). (B) Probability of overall survival for EML patients and non-EML patients. EML 5-year estimated overall survival 64% and non-EML 5-year estimated overall survival 73% (P log rank = 0.04). (C) Cumulative incidence of relapse for EML patients and non-EML patients. EML 5-year estimated relapse risk 33% and non-EML 5-year estimated relapse risk 49% (P log rank = 0. 16) reported in other studies. [22] [23] [24] [25] The higher frequency of M5 and the higher WBC observed in EML patients in our study may thus have contributed to the greater risk of induction death. EML was associated with MLL rearrangements, M5, and young age, thus increasing the risk of early death particularly from bleeding. The results highlight that an early diagnosis and particular attention with prompt initiation of supportive care measures may be crucial elements in the treatment of EML patients.
In this study, EML at diagnosis did not adversely affect the 5-year estimated EFS, possibly attributed to a lower risk of relapse in these patients. There is no consensus among study groups regarding the prognostic significance of EML. In a report from the St. Jude Children's Research Hospital, CNS involvement was not found to be associated with a poorer survival. 11 Yet, a correlation between the presence of CNS disease at diagnosis and an increased risk of isolated CNS relapse has been identified. 12, 13 Some studies have described significant differences in outcomes for patients with different subtypes of EML 9, 10, 14 as opposed to a study conducted by the Dutch Childhood Leukemia Study Group. 8 We found similar outcomes for the EML subgroups; however, the subgroups were small and data should be interpreted cautiously.
We found that EML was associated with young age, hepatomegaly, splenomegaly, a high initial WBC, M5 morphology, and 11q23/MLL rearrangements. Patients affected with myeloid sarcoma were younger and had more often FAB M5 and t(9;11), while CNS disease patients had a significantly higher initial WBC and more often M4 morphology. These characteristics are consistent with those reported in previous studies. 8, 9, 13, 14, [26] [27] [28] In addition, the literature suggests that patients with skin EML are young with 11q23 aberrations, whereas patients with orbital EML are older with t(8;21). 10, 14, 29 We found a similar pattern in our study cohort.
Generally, 11q23 aberrations are considered unfavorable cytogenetic features, conferring an intermediate 30 or a poor prognosis 31, 32 in children with AML. A large international study 33 identified major differences within 11q23/MLL-rearranged pediatric AML, including a poor prognosis in patients with t(10;11)(p11.2;q23) and t(10;11)(p12;q23). In this study, adjustment for 11q23 aberrations did not alter the risk estimates in 5-year OS for EML versus non-EML patients, suggesting that the poorer OS in EML patients could not be explained by the higher frequency of 11q23/MLL rearrangements in these patients.
An unexpected finding in our study was that blood contamination of the spinal fluid with no detectable blasts did not seem to have a negative impact on the survival. Traumatic lumbar puncture is associated with an inferior outcome in patients with acute lymphoblastic leukemia 34, 35 ; however, our results indicate that this is not the case for AML patients. Our findings are supported by data from COG and St.
Jude, 36 suggesting that CNS2 patients treated in accordance with the AML02 protocol with standard management of CNS2 patients had a better OS than CNS1 and CNS3 patients. Further studies are needed in order to draw any conclusions.
The role of radiotherapy in the treatment of EML is controversial with lacking evidence for the benefit and the risk of long-term morbidity and mortality. [37] [38] [39] [40] None of the NOPHO EML patients received radiotherapy as part of their primary treatment. The number of local relapses was low with four patients (5%) experiencing an isolated CNS or concurrent CNS and BM relapse. No patients in our cohort relapsed at the primary site of the myeloid sarcoma, thus strengthening the argument against the need of local radiotherapy of myeloid sarcoma. F I G U R E 2 Risk difference in overall survival at 5 years after diagnosis for EML patients versus non-EML patients stratified according to sex, age at diagnosis, initial WBC, FAB type, and 11q23 aberrations. The crude risk difference in 5-year overall survival (-9%) is marked by the dotted line. EML, extramedullary leukemia; WBC, white blood cell count; FAB, French-American-British; MLL, mixed lineage leukemia
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The present study is population based, including all incident cases in the Nordic countries with no loss to follow-up, thus excluding the risk of selection bias. All patients were treated according to the same protocol, karyotypes were centrally reviewed and available for 100% of the patients, and data were prospectively collected. The diagnosis of myeloid sarcoma may have been subject to nondifferential misclassification in patients in whom the tumor was not clinically obvious. Small sample sizes for some subgroups limit the ability to draw robust conclusions.
In conclusion, this population-based study identified a significantly higher frequency of induction deaths among EML patients. Early diagnosis and vigorous supportive care, especially during the induction, may be essential components in the attempt to improve the survival of these patients. There seems to be no role for radiotherapy in the primary treatment of EML patients with current intensive chemotherapy regimens. 
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